Simon Chowdury, MD, PhD, from the Sarah Cannon Research Institute, London, UK, talks to us about the undesirable outcomes from research on combining immune checkpoint inhibitors with tyrosine kinase inhibitors (TKIs) for the treatment of prostate cancer, namely hepatoxicity. Although disappointing, he notes that there is still potential for combination therapy in treating prostate cancer. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.